Company intelligence / Profile preview

Kronos Health

San Mateo, California, United Stateskronoshealth.com ↗

Ownership: Private
Employees: ~8
Development stage: Commercial

Overview

Kronos Bio previously advanced istisociclib, a CDK9 inhibitor, into Phase 1/2 trials for ovarian cancer but discontinued development in November 2024 due to neurological adverse events. The company’s pipeline now consists only of preclinical KAT inhibitors targeting p300 for multiple myeloma, HPV-driven cancers, and Sjögren’s disease. No current clinical results are available.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeSmall molecule microarray platform
Industry: Biotech

Partnerships

Genentech/Roche – partnership on several undisclosed discovery programs with significant milestone potential ($20M upfront plus up to $277M milestones per program/product)

Beyond the preview

Go deeper on Kronos Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kronos Health.

Explore the full profile